Kronos Bio, located in San Mateo (CA, corporate headquarters) and Cambridge (MA, R&D), was built on over a decade of research into high-throughput screening strategies for chemical modulators of transcription factors and other recalcitrant targets in oncology. By combining small molecule microarrays (SMM) developed at MIT by Angela Koehler with know-how in biological assay development, Kronos technology platform enables high-throughput screens of chemical libraries against target proteins in cell lysates. As a result, a single screening assay can identify compounds that bind or interfere with the target protein activity directly, disrupt protein-protein complexes, or affect nearest neighbor proteins that may indirectly modulate target activity. This approach is suited for discovery of unique ligands that can be utilized in the generation of novel modulators or degraders of historically challenging targets such as transcription factors.